4 de abril de 2020
18 de diciembre de 2008
- Comunicado -

Committee for Medicinal Products for Human Use (CHMP) Recommends Granting Marketing Authorisation for FIRMAGON(R) (degar


---------------------------------
(i) Van Poppel H, De La Rosette JJ, Persson B.E, Oleson TK, Degarelix
Study Group; Long-term evaluation of degarelix, a gonadotrophin-
releasing hormone (GnRH) receptor blocker, investigated in a
multicentre randomised study in prostate cancer (CAP) patients.
Abstract (23.) Euro Urol Suppl 2007;6(2):28
(ii) Boccon-Gibod L, Klotz L, Schroder FH, Andreou C, Persson BE, Cantor
P, Jensen JK, Olesen TK; Degarelix compared to leuprolide depot
7.5 mg in a 12-month randomised, open-label, parallel-group phase
III study in prostate cancer patients. Abstract 537 presented at
the 23rd EAU Congress, Milan, Italy, 2008.
(iii) Nielsen S, Connolly M, Persson B, Variation between countries in
the perceived use of antiandrogens to prevent flare symptoms:
results of a comprehensive survey. Abstract 539 presented at the
23rd EAU Congress, Milan, Italy, 2008
(iv) Gittelman M, Pommerville P, Persson B, Olesen T, A 1-year, open
label, randomised Phase II dose finding study of degarelix for the
treatment of prostate cancer in North America. Journal of Urology,
Vol. 180, November 2008.
(v) Tammela T, Iversen P, Johansson J, Persson B, Jensen J, Olesen T.
Degarelix-a phase II multicentre, randomised dose escalating study
testing a novel GnRH receptor blocker in prostate cancer patients
(Abstract No. 904) European Urology Supplements 4 (2005) No.3,
pp 228.

For further information please contact:

Katie Fyfe,
Tonic Life Communications,
Tel: +44-207-798-9920,
Katie.fyfe@toniclc.com .

Monica Gounaropoulos,
Tonic Life,
Communications,
Tel: +44-207-798-9910,
Monica.g@toniclc.com .

Helen Gallagher,
Ferring Pharmaceuticals,
Tel: +41-58-301-0051,
Helen.Gallagher@ferring.com .

For further information please contact: Katie Fyfe, Tonic Life Communications, Tel: +44-207-798-9920, Katie.fyfe@toniclc.com. Monica Gounaropoulos, Tonic Life, Communications, Tel: +44-207-798-9910, Monica.g@toniclc.com. Helen Gallagher, Ferring Pharmaceuticals, Tel: +41-58-301-0051, Helen.Gallagher@ferring.com.